The Neuroimaging and CSF Biomarker Program from the Alzheimer´s Drug Discovery Foundation provides funding to support the identification of biomarkers in Alzheimer´s disease. The grant is available to researchers worldwide, at both non-profit research institutions as well as for-profit organizations. This grant focuses on:
- Developing novel PET ligands for clinical trials
- Supporting novel CSF biomarkers
- Validating innovative MRI approaches in larger cohorts
- Developing novel measures of functional activity such as EEG
Applicants may apply for up to 600,000 USD (direct costs only) for 1 year with the potential for renewal. There are three assessment rounds per year. The next letter of intent is due February 5, 2024, and the full application is due on April 8, 2024.
April 8, 2024